Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
The current Regeneron(REGN) stock price is $807.40, with a market capitalization of 83.14B. The stock trades at a price-to-earnings (P/E) ratio of 19.33 and offers a dividend yield of 0.47%.
During the trading session on 2026-10-21, Regeneron(REGN) shares reached a daily high of $809.06 and a low of $789.69. At a current price of $807.40, the stock is +2.2% higher than the low and still -0.2% under the high.
Trading volume for Regeneron(REGN) stock has reached 619.4K, versus its average volume of 628.53K.
Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $572.75.
Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $572.75.
REGN News
...
The weight-loss market is growing rapidly, and while long-term projections differ on how large it will become, they generally agree that it will maintain its up...
Piper Sandler raised the firm’s price target on Regeneron (REGN) to $865 from $854 and keeps an Overweight rating on the shares. Ahead of Q3 2026 earnings for t...
Analyst ratings
65%
of 31 ratingsMore REGN News
Regeneron Pharmaceuticals reported new 84 week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva, showing sustained control o...
Regeneron Pharmaceuticals (NasdaqGS:REGN) received a positive opinion from the EMA’s CHMP for a new Libtayo dosing schedule across all approved uses. The CHMP-...
Regeneron (REGN) announced that the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has adopted an opinion recomme...
has delivered solid long term gains for shareholders over the past five years, and a fresh run of clinical and partnership news has pushed investors to reassess...
UBS upgraded Regeneron (REGN) to Buy from Neutral with a price target of $978, up from $660, after assuming coverage of the name. The shares at current levels a...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.